神經學緩釋治療藥物市場

使用旨在調節治療物質作用的製劑技術，藥物開發商正在開發具有緩釋特性的製劑。此類製劑技術包括聚乙二醇綴合物（聚乙二醇化）等聚合物，用於封裝和包覆新藥物。目的是透過控釋製劑滿足患者依賴性且依從性敏感的藥物治療方案的要求，例如多次給藥，透過每日一次或更少的給藥即可達到所需的治療效果。

鑑於慢性病持續需要重複給藥，這些適應症代表著巨大的藥物量和收入機會，同時挑戰該行業開發滿足非專業護理人員獨特需求的產品。對於設計供患者使用的藥物，特定治療的包裝可以提高依從性和治療結果。在藥物傳輸領域，設計用於容納預充式註射器和藥筒的可重複使用注射裝置正在提高使用便利性，並增加替代裝置在不斷增長的自我注射市場中的份額。

該報告研究了神經病學緩釋治療市場，並討論了新興國家的市場開發商、設備設計者和醫療保健行銷人員為患者自我管理而設計的注射設備的經濟、技術和機會。供應鏈。

目錄

執行摘要

市場機會

• 執行摘要
• 神經科藥物市場動態
• 自我管理傾向
• 給藥途徑
• 藥物配方創新
• 神經系統藥物和用品包裝
• 人體工學
• 神經科藥物注射給藥
• 初級包裝
• 注射裝置設計的創新
• 給藥裝置選擇問題
• 治療需求的驅動因素
• 關鍵市場因素
• MR神經產物分析
• 獨特的複合技術
• ChroniJect(Oakwood Laboratories/Pharma Sophia)
• CriticalMix(Critical Pharmaceutical)
• Depoform (Pasila)
• FluidCrystal（Camalus）
• LinkeRx（Alkermes）
• Medisorb（Alkermes）
• Medusa（Recifarm/Abadel）
• Nano crystal（Alkermes）
• Optisome（Talon/Spectrum）
• polyactive（Octoplus）
• Q-Sphera（Midatec Pharma）
• Saber/Saib（Durect）
• SynBiosys (Innocore)
• TransCon（ascendis）
• 物理製程控制方法
• 超臨界流體
• 用於奈米顆粒配方的 SCF
• Formulaplex（超臨界溶液）
• Ferro
• 乳液的 SCF 萃取 (SFEE)
• 穩定
• 管理因素
• 治療藥物市場領域
• 精神分裂症
• 躁鬱症
• 市場領域分析與預測
• 關鍵市場因素
• 經濟因素
• 技術要素
• 監管因素
• 風險因素
• 預測和市場數據
• 公司簡介

Using formulation technologies designed to modulate the effect of therapeutic substances, drug developers are creating formulations that exhibit extended release profiles. These chemistries include polymers such as polyethylene glycol-complexed (PEGylated), which are used to product encapsulated and coated versions of new APIs. The goal is to address the requirement for patient-dependent, and therefore compliance-sensitive, drug treatment protocols such as multiple dosing through controlled release formulations that provide the desired therapeutic effect with dosing of once-a-day or less.

The report provides developers, device designers, healthcare marketers, and supply chain participants with a detailed understanding of the economics, technologies, opportunities for injection devices that are designed for patient self-administration. Provider organization business managers, healthcare administrators and investors will also benefit from this study.

Evolution in Therapeutic Care

Because of the ongoing need for repeat dosing posed by chronic diseases, these indications represent significant drug volume and revenue opportunities, while simultaneously challenging the industry to develop products that meet the unique needs of the non-professional caregiver. For drugs designed to be administered by the patient, therapy-specific packaging is improving adherence and treatment outcomes. In the area of delivery, reusable injection devices designed to accept prefilled syringes or drug cartridges are improving ease-of-use and increasing the alternative device share of the growing self-injection market.

Features:

• Numerous graphs, charts, tables and visualizations complement the analysis

• Forecasts, projections of future market activity are derived using standard modeling and statistical techniques.

What You Will Learn:

• Analyzes and evaluates modified release neurology therapeutics products and assesses the market potential for existing and probable future products

• Analyzes product strategies, technologies and market development issues

• Provides detailed analysis of neurology market segments, market demographics, and therapeutic strategies

• Profiles market sector companies, their product development activities, business strategies, and corporate alliances and affiliations

• Evaluates the impact of economic, technology, and regulatory factors on neurology drug markets

Table of Contents

Executive Summary

The Market Opportunity

• Executive Summary
• The Neurological Drug Market Dynamics
• The Trend Toward Self-Administration
• Route of Administration
• Innovation in Drug Formulation
• Neurological Drugs and As-supplied Packaging
• Human Engineering/Ergonomics
• Delivering Neurological Drugs via Injection
• Primary Packaging
• Innovation in Injectable Device Designs
• Drug Delivery Device Selection Issues
• Therapeutic Demand Drivers
• Key Market Factors
• MR Neurological Product Analysis
• Proprietary Formulation Technology
• ChroniJect (Oakwood Laboratories/PharmaSophia)
• CriticalMix (Critical Pharmaceuticals)
• Depofoam (Pacira)
• FluidCrystal (Camarus)
• LinkeRx (Alkermes)
• Medisorb (Alkermes)
• Medusa (Recipharm/Avadel)
• Nanocrystals (Alkermes)
• Optisomes (Talon/Spectrum)
• PolyActive (Octoplus)
• Q-Sphera (Midatech Pharma)
• SABER/SAIB (DURECT)
• SynBiosys (Innocore)
• TransCon (Ascendis)
• Physical Process Control Methods
• Supercritical Fluid
• SCF for Nanoparticle Formulations
• Formulplex (Supercritical Solutions)
• Ferro
• SCF extraction of emulsions (SFEE)
• Stability
• Administration Factors
• Therapeutic Market Sectors
• Schizophrenia
• Bipolar Disorder
• Market Sector Analysis and Forecasts
• Key Market Factors
• Economic Factors
• Technology Factors
• Regulatory Factors
• Risk Factors
• Forecasts and Market Data
• Company Profiles